Arcutis 10-Q: Q3 Revenue $143.9M, Nine-Month Profit $12.5M, ATM Upsized to $200M
ARQT sits 62% above its 52-week low of $19.295.
Summary
Arcutis filed its Q3 2026 10-Q showing $143.9 million of product revenue, $12.5 million of nine-month net income and $259.8 million in cash, and disclosed a new $200 million at-the-market program alongside Robert Lisicki's permanent appointment as chief commercial officer.
Key Events · Earnings and Guidance · ARQT
-
Q3 Revenue Grows 45% to $143.9M
Net product revenue of $143.9 million rose 45% from $99.2 million in Q3 2025, led by ZORYVE foam at $75.1 million (+51%).
-
Nine-Month Swing to $12.5M Profit
Nine-month 2026 net income was $12.5 million versus a $33.5 million net loss a year earlier; Q3 net income was $8.8 million, or $0.06 diluted EPS.
-
ATM Capacity Doubled to $200M
A November 4, 2026 amended sales agreement with TD Securities raises the at-the-market program to $200.0 million from $100.0 million; no shares have been sold under either agreement.
-
Cash Covers At Least 12 Months
Cash, cash equivalents, restricted cash and marketable securities totaled $259.8 million at September 30, 2026, against $100.0 million of term debt outstanding.
Analysis · ARQT · Life Sciences
Two items in this quarterly report go beyond the same-day earnings release: a doubling of the at-the-market program to $200 million and a permanent chief commercial officer. The ATM is capacity, not a sale — no shares have been issued under it — but it gives management a ready lever to raise cash while the stock trades at $31.25, and it sits alongside $259.8 million of cash and marketable securities that the company says funds at least 12 months of operations. The income statement also shows the cost of growth: SG&A jumped 60% to $99.6 million in the quarter on the 'Skin to Believe In' campaign and an expanded sales force, which is why Q3 net income of $8.8 million came in below Q2's $15.0 million despite revenue rising 11% sequentially.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARQT was trading at $31.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $19.30 to $34.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.